Cargando…

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

INTRODUCTION: Patients with moderate-to-severe atopic dermatitis (AD) report a multidimensional disease burden that includes impaired health-related quality-of-life (HRQoL). Changes in overall health status and specific dimensions that contribute to HRQoL were evaluated in adults with moderate-to-se...

Descripción completa

Detalles Bibliográficos
Autor principal:	Simpson, Eric L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453923/ https://www.ncbi.nlm.nih.gov/pubmed/28503712 http://dx.doi.org/10.1007/s13555-017-0181-6

Ejemplares similares

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Dupilumab for atopic dermatitis
Publicado: (2019)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Blood Cells Count Derived Inflammation Indexes as Predictors of Early Treatment Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
por: Zinellu, Angelo, et al.
Publicado: (2023)

Dupilumab therapy following JAK inhibitor withdrawal in moderate–severe atopic dermatitis
por: Kiely, Lisa, et al.
Publicado: (2022)

Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis
por: Napolitano, Maddalena, et al.
Publicado: (2022)

Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
por: Ferrucci, Silvia, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

One-Year Effectiveness and Safety of Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Korean Patients: A Real-World Retrospective Analysis
por: Lee, Hanjae, et al.
Publicado: (2021)

New Onset of Alcohol Flushing in an Atopic Dermatitis Patient Treated with Dupilumab
por: Choi, Hoon, et al.
Publicado: (2023)

Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: A case report
por: Mian, Madeeha, et al.
Publicado: (2020)

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
por: Awosika, Olabola, et al.
Publicado: (2018)

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
por: Ungar, Benjamin, et al.
Publicado: (2022)

Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
por: MARESCHAL, Adrien, et al.
Publicado: (2020)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
por: Jang, Dong Hyek, et al.
Publicado: (2020)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea
por: Lee, Dong Hun, et al.
Publicado: (2022)

Work ability and quality of working life in atopic dermatitis patients treated with dupilumab
por: Bosma, Angela L., et al.
Publicado: (2021)

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
por: Kimball, Alexa B., et al.
Publicado: (2023)

Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
por: Miniotti, Marco, et al.
Publicado: (2022)

Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate‐to‐severe hidradenitis suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Does Monthly Dupilumab Therapy Maintain its Clinical Efficacy in Moderate-to-Severe Atopic Dermatitis?
por: Kim, Su Min, et al.
Publicado: (2021)

Rapid response to dupilumab treatment in children with moderate‐to‐severe atopic dermatitis: A case series
por: Votto, Martina, et al.
Publicado: (2022)

Improve the dupilumab therapy evaluation with dermoscopy and high‐frequency ultrasound in moderate‐to‐severe atopic dermatitis
por: Liu, Zhaorui, et al.
Publicado: (2022)

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Peterson, Danielle M., et al.
Publicado: (2021)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
por: Giavina-Bianchi, Mara, et al.
Publicado: (2021)

Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer
por: Tanczosova, Milena, et al.
Publicado: (2023)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rp92gsvkqasesmjfl4r0t3552r